Osteoblast-derived growth factors enhance adriamycin-cytostasis of MCF-7 human breast cancer cells

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4213-4224

  Choki, Isabelle ^a   Sourla, Antigone ^a   Reyes Moreno, Carlos ^a   Koutsilieris, Michael ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adriamycin; Bone metastasis; Breast cancer; Cytostasis

Indexed keywords

AGAROSE; ANTINEOPLASTIC AGENT; DNA FRAGMENT; DOXORUBICIN; ESTRADIOL; ESTROGEN RECEPTOR; GROWTH FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSTASIS; CYTOTOXICITY; DISEASE COURSE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CULTURE MEDIA, CONDITIONED; DNA FRAGMENTATION; DOXORUBICIN; DRUG SYNERGISM; ESTRADIOL; FEMALE; G2 PHASE; GROWTH SUBSTANCES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MITOSIS; OSTEOBLASTS; OSTEOSARCOMA; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0032410113     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Boring CC, Squires TS and Tong T: Cancer statistics. CA Cancer J Clin 43: 7-26, 1993.
2. Koenders PG, Beex LVAM, Langens R, Kloppenborg PWC, Smalls AGH, Benraad, TJ and the Breast Cancer Study Group: Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. Breast Cancer Res Treat 18: 27-32, 1991.
3. Theriaultr RL and Hortobagyl GN: Bone metastasis in breast cancer. Anti Cancer Drugs 3: 455-462, 1992.
4. Galasco CSB: Mechanisms of lytic and blastic metastatIc disease of bone. Clin Orthopaed Rel Res 12: 20-27, 1982.
5. Evans CE, Ward C and Braidman IP: Breast carcinomas synthesize factors which influence osteoblast-like cells indecently of osteoclast in vitro. J Endocrinol 128: R5-R8, 1991.
6. Taube T, Elomaa I, Blomqvist C, Beneton MNC and Kanis JA: Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 15, 2: 161-166, 1994.
7. Grondahl-Hanseb J, Christensen J, Rosenquist C., Brunner N, Mouridsen HT, Dano K and Blichert-Toft M: High level of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
8. Koutsilieris M and Polychronakos Proteolytic activity against IGF-binding proteins involved in paracrine interactions prostate adenocarcinoma cells and osteoblasts. Anticancer Res., 12: 905-910, 1992.
9. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV and Polychronakos C: Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. AnticancerRes 13: 481-486, 1993.
10. Sherry MM, Greco AF, Johnson DH and Hainsmorth JD: Metastatic breast cancer confined to the skeletal system. Am J Med 81: 381-386, 1986.
11. Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987.
12. Diel IJ, Kaufman M, GoernerR, Costa SD, Kaul Sand Bastert G: Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis. J Clin Oncol 10: 21534-1539, 1992.
13. Kyprianou N, English HF, Davidson NE and Isaacs IT, Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 53: 162-166, 1991.
14. Teixeira C, Reed JC and Pratt MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
15. Boulanger J, Reyes-Moreno C and Koutsilieris M: Mediation of the glucocorticoid receptor (GR) function by the activation of latent transforming growth factor beta 1 in MG-63 osteoblasts-like osteosarcoma cells. Int J Cancer 62: 692-697, 1995.
16. Koutsilieris M, Reyes-Moreno C, Sourla A, Dimitriadou V and Choki I: Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res 17: 1461 -1465, 1997.
17. Koutsilieris M, Sourla A, Pelletier G and Doillon C: Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastastic prostate cancer. J Bone Miner Res 9: 1823-1832, 1994.
18. Sourla A, Doillon C and Koutsilieris, M. Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells. Anticancer Res 16: 2773-2780, 1996.